# ACR/ARP Medication Guide

AMERICAN COLLEGE of RHEUMATOLOGY Empowering Rheumatology Professionals

ASSOCIATION of
RHEUMATOLOGY
PROFESSIONALS
The Interprofessional Division of the
American College of Rheumatology

## **Ustekinumab (Stelara®)**

Ustekinumab is a human immunoglobulin G1k monoclonal antibody that binds to the p40 subunit of the following cytokines: interleukin-12 (IL-12) and interleukin-23 (IL-23).

#### **Resources from Manufacturer**

Patient Medication Guide
Full Prescribing Information
Patient Support Program
Financial Assistance

### FDA-Approved Indications and Dosing in Rheumatology

Ustekinumab is indicated for psoriatic arthritis (PsA) in adults and pediatric patients  $\geq$  6 years old Subcutaneous dosing: Initial dose at week 0 and week 4 then every 12 weeks thereafter

- PsA: 45 mg
- Coexistent PsA and moderate to severe plaque psoriasis in patients >100 kg: 90 mg
- Pediatric JIA (weight-based dosing)

Weight	Dosing
< 60 kg	0.75 mg/kg
60 – 100 kg	45 mg
> 100 kg with co-existent moderate to severe psoriasis	90 mg

#### **Contraindications**

Hypersensitivity to ustekinumab or any of its excipients

## **Warnings and Precautions**

- 1. Serious infections including tuberculosis and invasive fungal infections—avoid starting during active infection. If an infection develops, monitor carefully and hold therapy if serious.
- 2. Malignancies have been reported
- 3. Hypersensitivity reactions including anaphylaxis and angioedema have been reported
- 4. Posterior reversible encephalopathy syndrome (PRES) has been reported
- 5. Noninfectious pneumonia has been reported
- 6. Avoid live vaccines while on treatment

# ACR/ARP Medication Guide

AMERICAN COLLEGE of RHEUMATOLOGY Empowering Rheumatology Professionals

ASSOCIATION of
RHEUMATOLOGY
PROFESSIONALS
The Interprofessional Division of the
American College of Rheumatology

### Adverse Reactions (≥ 3%)

- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Fatique

## **Medication Strength and Preparations**

- Single-dose prefilled syringe: 45 mg/0.5 mL; 90 mg/mL
- Solution in single-dose vial: 45 mg/0.5 mL

### **Medication Administration and Storage**

- Store in original carton to protect from light
- Store in refrigerator at 2°C to 8°C [36°F to 46°F] do not freeze
- Inject subcutaneously into front of thigh, abdomen (avoid injecting within 2 inches of navel), outer upper arms, or buttocks
- Do not administer into tender, bruised, red or hard skin, or areas where psoriasis is present
- Insert the needle into pinched skin at 45-degree angle
- Pre-filled syringes are safe at room temperature (defined as up to 30°C (86°F)) for up to 30 days
- Needle cover on the prefilled syringe contains dry natural rubber [latex derivative]

#### Intravenous Administration Pre-Infusion Checklist continued

#### **Managing Infusion Reactions**

- 1. Acute infusion reaction can occur during the administration of tocilizumab or within 24 hours of infusion. If the patient reports mild reactions (such as flushing, chills, etc.), slow down the infusion rate and assess the patient. Notify the supervising provider of the reaction.
- 2. For more severe reactions (such as hives, difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, fever, chills or anaphylaxis) or when mild reactions persist despite slowing the infusion, stop the infusion and treat the acute reaction. Tocilizumab should not be given to patients who have experienced anaphylaxis or other severe hypersensitivity and not re-challenged.

#### **Updated June 2023-ARP Practice Committee**

DISCLAIMER: The information contained in this biologic reference guide is published by the American College of Rheumatology ("ACR") for informational purposes only, in furtherance of its educational mission. It is not a substitute for user's independent medical discretion or decision making, nor a replacement for the manufacturer's complete prescribing and labeling information, as in effect at the time of use. The information contained herein reflects the conclusions of the individual companies who manufacture the products and not those of the ACR. ACR does not endorse or make any statement regarding the efficacy or safety of any of the listed companies or any of their drugs or other products. ACR specifically disclaims any and all responsibility or liability for the accuracy or completeness of the contents of this reference guide, the use of such information by anyone and/or for the performance of any of the drugs listed in this biologic reference guide (including without limitation, any adverse effects).